TY - JOUR
T1 - Estrogen receptor β (ESR2) polymorphisms and endometrial cancer (United States)
AU - Setiawan, Veronica Wendy
AU - E.Hankinson, Susan
AU - A.Colditz, Graham
AU - J.Hunter, David
AU - Vivo, Immaculata De
N1 - Funding Information:
This work is supported by National Institute of Health Grants: T32CA09001-27 [V.W.S.], CA82838 [I.D.], CA49449 [S.E.H], CA87969 [G.A.C.], and a grant from the American Cancer Society: RSG-00-061-04-CCE. We thank Robert O’Brien, Hardeep Ranu and Rong Chen for their technical assistance. We are also indebted to the participants in the Nurses’ Health Study for their dedication and commitment.
PY - 2004/8
Y1 - 2004/8
N2 - Objective: We hypothesized that variations in the ESR2 gene may influence estrogen exposure in the uterus and thus influence endometrial cancer risk. We validated and screened for variants in the ESR2 gene and examined whether they are associated with endometrial cancer risk. Methods: We resequenced the promoter and coding regions of the ESR2 gene in 24 endometrial cancer cases, and genotyped the validated/discovered SNPs and intronic dinucleotide CA repeat in a nested case-control study of endometrial cancer (cases = 222, controls = 666) in the Nurses' Health Study (NHS). We also explored statistical interaction between ESR2 genotypes and body mass index (BMI) or hormone replacement therapy (HRT) use among postmenopausal women and cancer risk. Results: Two SNPs were validated [rs1256049 in exon 5 (allelic frequencies = 98% G, 2% A) and rs1271572 in the promoter region (allelic frequencies = 60% G, 40% T)]. After adjusting for potential confounders, we observed no association between ESR2 gene polymorphisms and endometrial cancer risk [rs1256049 (OR = 1.2; 95%CI: 0.7-2.3), rs1271572 (OR = 0.8; 95%CI: 0.5-1.1) and CA repeat (22 repeat allele versus ≥22 repeat allele, OR = 1.1; 95%CI: 0.7-1.7)]. We also did not observe any significant effect modification of the ESR2 polymorphisms by BMI or HRT use among postmenopausal women. Conclusion: Our results indicate that ESR2 polymorphisms may not be associated with endometrial cancer risk.
AB - Objective: We hypothesized that variations in the ESR2 gene may influence estrogen exposure in the uterus and thus influence endometrial cancer risk. We validated and screened for variants in the ESR2 gene and examined whether they are associated with endometrial cancer risk. Methods: We resequenced the promoter and coding regions of the ESR2 gene in 24 endometrial cancer cases, and genotyped the validated/discovered SNPs and intronic dinucleotide CA repeat in a nested case-control study of endometrial cancer (cases = 222, controls = 666) in the Nurses' Health Study (NHS). We also explored statistical interaction between ESR2 genotypes and body mass index (BMI) or hormone replacement therapy (HRT) use among postmenopausal women and cancer risk. Results: Two SNPs were validated [rs1256049 in exon 5 (allelic frequencies = 98% G, 2% A) and rs1271572 in the promoter region (allelic frequencies = 60% G, 40% T)]. After adjusting for potential confounders, we observed no association between ESR2 gene polymorphisms and endometrial cancer risk [rs1256049 (OR = 1.2; 95%CI: 0.7-2.3), rs1271572 (OR = 0.8; 95%CI: 0.5-1.1) and CA repeat (22 repeat allele versus ≥22 repeat allele, OR = 1.1; 95%CI: 0.7-1.7)]. We also did not observe any significant effect modification of the ESR2 polymorphisms by BMI or HRT use among postmenopausal women. Conclusion: Our results indicate that ESR2 polymorphisms may not be associated with endometrial cancer risk.
KW - ESR2
KW - endometrial cancer
KW - estrogen receptor β
KW - polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=4043150721&partnerID=8YFLogxK
U2 - 10.1023/B:CACO.0000036170.28502.5f
DO - 10.1023/B:CACO.0000036170.28502.5f
M3 - Article
C2 - 15280642
AN - SCOPUS:4043150721
SN - 0957-5243
VL - 15
SP - 627
EP - 633
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 6
ER -